Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Executive Summary

Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.

Advertisement

Related Content

After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS
Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market
New Mechanism And Oral Activity Underline Selinexor's Role In Multiple Myeloma
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer
AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
Global Blood Takes HOPE In Sickle Cell After Pulmonary Fibrosis Failure
Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel